CN106164072B - 用于治疗细菌感染的单环内酰胺有机化合物 - Google Patents

用于治疗细菌感染的单环内酰胺有机化合物 Download PDF

Info

Publication number
CN106164072B
CN106164072B CN201580015867.7A CN201580015867A CN106164072B CN 106164072 B CN106164072 B CN 106164072B CN 201580015867 A CN201580015867 A CN 201580015867A CN 106164072 B CN106164072 B CN 106164072B
Authority
CN
China
Prior art keywords
amino
mmol
methyl
tert
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580015867.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106164072A (zh
Inventor
V·S·奥拉克
A·卡萨雷兹
X·林
M·林德瓦尔
G·麦肯罗
H·E·莫泽
F·雷克
M·钱德拉
R·L·西蒙斯
A·伊弗鲁
朱庆明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN106164072A publication Critical patent/CN106164072A/zh
Application granted granted Critical
Publication of CN106164072B publication Critical patent/CN106164072B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580015867.7A 2014-03-24 2015-03-23 用于治疗细菌感染的单环内酰胺有机化合物 Active CN106164072B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461969735P 2014-03-24 2014-03-24
US61/969,735 2014-03-24
US201462088304P 2014-12-05 2014-12-05
US62/088,304 2014-12-05
PCT/US2015/022011 WO2015148379A1 (en) 2014-03-24 2015-03-23 Monobactam organic compounds for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
CN106164072A CN106164072A (zh) 2016-11-23
CN106164072B true CN106164072B (zh) 2019-10-01

Family

ID=52808201

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580015867.7A Active CN106164072B (zh) 2014-03-24 2015-03-23 用于治疗细菌感染的单环内酰胺有机化合物

Country Status (37)

Country Link
US (4) US9174978B2 (enExample)
EP (2) EP3511328B1 (enExample)
JP (1) JP6153674B2 (enExample)
KR (1) KR101733441B1 (enExample)
CN (1) CN106164072B (enExample)
AP (1) AP2016009374A0 (enExample)
AU (1) AU2015236369B2 (enExample)
BR (1) BR112016020333B1 (enExample)
CA (1) CA2939254C (enExample)
CL (1) CL2016002285A1 (enExample)
CU (1) CU24441B1 (enExample)
CY (1) CY1121701T1 (enExample)
DK (2) DK3122745T3 (enExample)
EA (1) EA030850B1 (enExample)
EC (1) ECSP16073620A (enExample)
ES (2) ES2862203T3 (enExample)
GT (1) GT201600183A (enExample)
HR (1) HRP20190501T1 (enExample)
HU (1) HUE042134T2 (enExample)
IL (1) IL247259B (enExample)
LT (1) LT3122745T (enExample)
MA (1) MA39777B1 (enExample)
MX (1) MX373444B (enExample)
MY (1) MY179292A (enExample)
PE (1) PE20161371A1 (enExample)
PH (1) PH12016501577B1 (enExample)
PL (1) PL3122745T3 (enExample)
PT (1) PT3122745T (enExample)
RS (1) RS58509B1 (enExample)
SG (1) SG11201606711UA (enExample)
SI (1) SI3122745T1 (enExample)
SM (1) SMT201900218T1 (enExample)
SV (1) SV2016005274A (enExample)
TW (1) TWI714525B (enExample)
UA (1) UA121383C2 (enExample)
WO (1) WO2015148379A1 (enExample)
ZA (1) ZA201605565B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2785715C1 (ru) * 2018-12-18 2022-12-12 Медшайн Дискавери Инк. ПРИМЕНЕНИЕ МОНОЦИКЛИЧЕСКОГО β-ЛАКТАМНОГО СОЕДИНЕНИЯ В ФАРМАЦИИ

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092620A1 (ru) * 2015-09-23 2021-06-30 Новартис Аг Соли и твердые формы монобактамного антибиотика
WO2017081615A1 (en) 2015-11-09 2017-05-18 Wockhardt Limited 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections
CA3008006C (en) 2015-12-15 2024-04-09 Merck Sharp & Dohme Corp. Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
KR102408800B1 (ko) 2016-03-07 2022-06-13 머크 샤프 앤드 돔 코포레이션 비시클릭 아릴 모노박탐 화합물 및 박테리아 감염의 치료를 위한 그의 사용 방법
ES2966369T3 (es) 2017-03-20 2024-04-22 Broad Inst Inc Compuestos y métodos para el tratamiento de enfermedades parasitarias
CN111094281B (zh) * 2017-08-02 2023-08-29 诺华股份有限公司 用于制备单内酰胺抗生素的化学方法及其中间体
WO2019058346A1 (en) * 2017-09-22 2019-03-28 Novartis Ag MONOBACTAM ADMINISTRATION IN ASSOCIATION WITH ANTIBIOTIC AGENT FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
SG11202002575UA (en) 2017-10-02 2020-04-29 Merck Sharp & Dohme Chromane monobactam compounds for the treatment of bacterial infections
SG11202002300QA (en) * 2017-10-02 2020-04-29 Arixa Pharmaceuticals Inc Aztreonam derivatives and uses thereof
WO2019092180A1 (en) * 2017-11-10 2019-05-16 Novartis Ag Administration of monobactam for the treatment of urinary tract infection
US11459323B2 (en) 2018-01-29 2022-10-04 Medshine Discovery Inc. Monocyclic β-lactam compound for treating bacterial infection
KR102017784B1 (ko) * 2018-04-11 2019-09-03 전북대학교산학협력단 민감성 및 선택성을 개선한 캠필로박터 검출용 배지 조성물 및 이를 이용한 캠필로박터 검출방법
KR102017785B1 (ko) * 2018-05-17 2019-09-03 전북대학교산학협력단 민감성 및 선택성을 개선한 캠필로박터 선택증균용 배지 조성물 및 이를 이용한 캠필로박터 검출방법
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
IL280770B2 (en) 2018-08-09 2024-05-01 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
TW202024068A (zh) 2018-11-13 2020-07-01 大陸商南京聖和藥業股份有限公司 單環內醯胺化合物及其應用
JP7179185B2 (ja) * 2018-12-18 2022-11-28 メッドシャイン ディスカバリー インコーポレイテッド 医薬の製造おける単環式β－ラクタム化合物の使用
KR102786898B1 (ko) * 2019-11-22 2025-03-25 쑤저우 얼예 파마슈티칼 컴퍼니 리미티드 설포닐우레아 고리 치환 모노시클릭 β-락탐계 항생제
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
US12491180B2 (en) 2019-12-19 2025-12-09 Shenzhen Optimum Biological Technology Co., Ltd Application of compound in treating pneumonia
EP3838266A1 (en) 2019-12-20 2021-06-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microfluidic production of biofunctionalized giant unilamellar vesicles for targeted intracellular cargo delivery
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
EP4165039B1 (en) * 2020-07-16 2024-08-21 Ningxia Academy of Agriculture and Forestry Sciences Novel monobactam compounds, their preparation and use as antibacterial agents
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
KR20240105442A (ko) 2021-11-18 2024-07-05 머크 샤프 앤드 돔 엘엘씨 크로만 아미딘 모노박탐 항생제
CN115304594B (zh) 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0053816A1 (en) * 1980-12-05 1982-06-16 Takeda Chemical Industries, Ltd. 1-Sulfo-2-oxoazetidine derivatives, their production and use
EP0093376A2 (en) * 1982-04-30 1983-11-09 Takeda Chemical Industries, Ltd. 1-Sulfo-2-azetidinone derivatives, their production and use
CN103228652A (zh) * 2010-11-29 2013-07-31 辉瑞大药厂 单环内酰胺类

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196202A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Beta-lactam antibiotics (of azetidine-sulphonic acid type)
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
EP0048953B1 (en) 1980-09-29 1988-03-09 E.R. Squibb & Sons, Inc. Beta-lactam antibiotics
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd １−スルホ−２−オキソアゼチジン誘導体、その製造法および用途
US4782147A (en) * 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
JPS58189176A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd １−スルホ−２−アゼチジノン誘導体およびその製造法
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
HU189290B (en) 1982-05-31 1986-06-30 Banyu Pharmaceutical Co Ltd,Jp Process for preparing new 2-oxo-1-azetidine-sulphonic acid derivatives and pharmaceutically acceptable salts thereof, further pharmaceutical compositions containing such derivatives as active substances
EP0096297B1 (de) 1982-06-03 1988-06-15 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von 1-Sulfo-2-oxoazetidinderivaten
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd ２−オキソ−１−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
JP2001520039A (ja) 1997-10-21 2001-10-30 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２
WO1999040196A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
ES2295040T3 (es) 1999-07-12 2008-04-16 Genentech, Inc. Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US7618632B2 (en) 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
EP2069347A2 (en) 2006-09-27 2009-06-17 Merck & Co., Inc. Novel inhibitors of beta-lactamase
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
DK2175884T3 (en) 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
DK2231667T3 (da) 2008-01-18 2013-12-16 Merck Sharp & Dohme Beta-lactamase-hæmmere
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX2011002250A (es) 2008-08-25 2011-08-17 Amplimmune Inc Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
KR101655961B1 (ko) 2008-10-31 2016-09-08 시오노기세야쿠 가부시키가이샤 카테콜기를 갖는 세팔로스포린류
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
SG178991A1 (en) 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011061760A1 (en) 2009-11-18 2011-05-26 Cadila Healthcare Limited Novel antithrombotic agents
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
PT2519543T (pt) 2009-12-29 2016-10-07 Emergent Product Dev Seattle Proteínas de ligação de heterodímero e suas utilizações
JP2012027846A (ja) 2010-07-27 2012-02-09 Sony Corp 情報処理装置、情報表示方法及びコンピュータプログラム
PL2748151T3 (pl) 2011-08-25 2016-09-30 Pirymidynowe inhibitory pde10
EP3052497B1 (en) 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
AU2013237939A1 (en) 2012-03-30 2014-10-30 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
MX2014011825A (es) 2012-03-30 2015-02-20 Cubist Pharm Inc INHIBIDORES DE ISOXAZOL ß-LACTAMASA.
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
AU2013308127B2 (en) 2012-08-25 2015-08-13 Wockhardt Limited 1,6- Diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US20160326157A1 (en) 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0053816A1 (en) * 1980-12-05 1982-06-16 Takeda Chemical Industries, Ltd. 1-Sulfo-2-oxoazetidine derivatives, their production and use
EP0093376A2 (en) * 1982-04-30 1983-11-09 Takeda Chemical Industries, Ltd. 1-Sulfo-2-azetidinone derivatives, their production and use
CN103228652A (zh) * 2010-11-29 2013-07-31 辉瑞大药厂 单环内酰胺类

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2785715C1 (ru) * 2018-12-18 2022-12-12 Медшайн Дискавери Инк. ПРИМЕНЕНИЕ МОНОЦИКЛИЧЕСКОГО β-ЛАКТАМНОГО СОЕДИНЕНИЯ В ФАРМАЦИИ

Also Published As

Publication number Publication date
CA2939254C (en) 2023-02-14
US10369138B2 (en) 2019-08-06
MA39777B1 (fr) 2019-03-29
EP3122745A1 (en) 2017-02-01
UA121383C2 (uk) 2020-05-25
JP2017510580A (ja) 2017-04-13
ES2862203T3 (es) 2021-10-07
PH12016501577B1 (en) 2022-04-29
SV2016005274A (es) 2018-06-12
BR112016020333B1 (pt) 2022-08-09
PH12016501577A1 (en) 2016-10-03
IL247259A0 (en) 2016-09-29
ECSP16073620A (es) 2018-12-31
AP2016009374A0 (en) 2016-08-31
PE20161371A1 (es) 2016-12-21
KR101733441B1 (ko) 2017-05-10
CL2016002285A1 (es) 2016-12-30
EP3511328A1 (en) 2019-07-17
ZA201605565B (en) 2017-09-27
WO2015148379A1 (en) 2015-10-01
ES2719136T3 (es) 2019-07-08
US20160051523A1 (en) 2016-02-25
IL247259B (en) 2020-02-27
MX2016011822A (es) 2016-12-02
PL3122745T3 (pl) 2019-08-30
KR20160110541A (ko) 2016-09-21
DK3511328T3 (da) 2021-03-22
MY179292A (en) 2020-11-03
CU24441B1 (es) 2019-09-04
HUE042134T2 (hu) 2019-06-28
CN106164072A (zh) 2016-11-23
SI3122745T1 (sl) 2019-05-31
US9174978B2 (en) 2015-11-03
NZ723114A (en) 2020-12-18
MA39777A (fr) 2017-02-01
JP6153674B2 (ja) 2017-06-28
EA030850B1 (ru) 2018-10-31
RS58509B1 (sr) 2019-04-30
AU2015236369B2 (en) 2017-02-16
CA2939254A1 (en) 2015-10-01
SMT201900218T1 (it) 2019-05-10
HRP20190501T1 (hr) 2019-05-03
CY1121701T1 (el) 2020-07-31
MX373444B (es) 2020-04-30
CU20160131A7 (es) 2017-02-02
EA201691766A1 (ru) 2016-12-30
PT3122745T (pt) 2019-04-30
AU2015236369A1 (en) 2016-09-01
US20190231752A1 (en) 2019-08-01
TW201540712A (zh) 2015-11-01
BR112016020333A2 (pt) 2017-10-24
EP3511328B1 (en) 2021-03-03
US20150266867A1 (en) 2015-09-24
EP3122745B1 (en) 2019-02-27
SG11201606711UA (en) 2016-10-28
US20200276169A1 (en) 2020-09-03
TWI714525B (zh) 2021-01-01
GT201600183A (es) 2018-12-18
LT3122745T (lt) 2019-04-10
DK3122745T3 (en) 2019-04-08

Similar Documents

Publication Publication Date Title
CN106164072B (zh) 用于治疗细菌感染的单环内酰胺有机化合物
CN109071504B (zh) 受体相互作用蛋白激酶1的抑制剂
CN112004817A (zh) 作为囊性纤维化跨膜传导调节因子的调节剂的大环化合物、其药物组合物、它们在治疗囊性纤维化中的用途，以及它们的制备方法
CN112262139A (zh) 作为激酶抑制剂的氨基吡咯并三嗪
CN113056305A (zh) 化合物
KR20230024361A (ko) Il-17의 소분자 조절제
CN113929680A (zh) 杂环化合物及它们在预防或治疗细菌感染中的应用
TWI746652B (zh) β-內醯胺酶抑制劑
HK1230592B (en) Monobactam organic compounds for the treatment of bacterial infections
HK1230592A1 (en) Monobactam organic compounds for the treatment of bacterial infections
HK40068840B (zh) 稠合吡啶酮类化合物及其制备方法和应用
NZ723114B2 (en) Monobactam organic compounds for the treatment of bacterial infections
HK40049641A (en) Biphenyl derivative inhibitor, preparation method therefor and use
HK40002917B (zh) 杂环化合物及它们在预防或治疗细菌感染中的应用
HK40002917A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant